Back to Search
Start Over
Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report
- Source :
- OncoTargets and Therapy.
- Publication Year :
- 2017
- Publisher :
- Dove Press, 2017.
-
Abstract
- Fu-Chao Ma,1 Qian Yu,1 Zhi-Ming Zeng,1 Rong-Quan He,1 Chao-Hua Mo,2 Jin-Cai Zhong,1 Jie Ma,1 Zhen-Bo Feng,2 Gang Chen,2 Xiao-Hua Hu1 1Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, 2Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China Abstract: Intrahepatic cholangiocarcinoma (ICC) arises from the biliary epithelium and is a relatively rare and highly fatal neoplasm. The prognosis is poor, and survival is limited to a few months. Here, we report a case of advanced ICC that was successfully treated with apatinib, a new oral tyrosine kinase inhibitor that targets the intracellular domain of vascular endothelial growth factor receptor-2. To the best of our knowledge, this is the first case report of the successful use of apatinib for advanced ICC; this treatment has demonstrated fewer toxic effects than traditional cytotoxic chemotherapy. The progression-free survival time was 8 months. The only toxicity observed was mild hand–foot syndrome. Therefore, apatinib may be an additional option for the treatment of advanced ICC, but further prospective studies are needed to optimize the treatment. Keywords: advanced intrahepatic cholangiocarcinoma, apatinib, PFS, cholangiocarcinoma, VEGFR-2, targeted therapy
- Subjects :
- OncoTargets and Therapy
Subjects
Details
- Language :
- English
- ISSN :
- 11786930
- Database :
- OpenAIRE
- Journal :
- OncoTargets and Therapy
- Accession number :
- edsair.dovemedicalp..e26b9c73e08370306ba477796e5982dd